NeuroMarket Pulse — July 15, 2026
| FDA clearance of Leqembi IQLIK’s 500 mg subcutaneous initiation dose makes lecanemab the first anti-amyloid therapy with a fully at-home pathway from initiation through maintenance, handing Eisai and Biogen a late-August launch window and a convenience edge over Lilly’s IV-only Kisunla — as AAIC 2026 pivots the field’s next battle toward tau.
Today’s top developments:
|
What to Watch
- Leqembi IQLIK’s late-August at-home launch — the first real-world test of subcutaneous anti-amyloid uptake; watch prescription velocity versus IV Leqembi, payer prior-authorization turnaround, and any ARIA events in the home setting where monitoring differs from infusion centers.
- Tavapadon PDUFA decision, expected around July 2026 — AbbVie’s first-in-class D1/D5 partial agonist (NDA filed September 26, 2025) could open the first new mechanistic class in Parkinson’s symptomatic therapy in over a decade and validate the Cerevel acquisition.
- Biogen’s diranersen Phase 3 design call — dose selection against a flat dose-response, and whether to run monotherapy or a lecanemab-combination trial, is the most consequential Alzheimer’s pipeline decision of the next six months; expect a design or IND update by Q4 2026.
- MS BTK-inhibitor class inflection — Roche’s fenebrutinib (Phase 3-positive in RMS and PPMS) targets an H1 2026 filing that could yield a Q4 2026–Q1 2027 PDUFA, while Sanofi’s tolebrutinib CRL from December 2025 remains unresolved — a potential first-to-market swing in the class.
This brief highlights the edition’s top stories. Read the full July 15, 2026 edition → for all stories and analysis — or browse the NeuroMarket Pulse archive.